Interventional CT represents a strategic opportunity for Medrad. The company has signed its second distribution agreement in three months, this one with Lakewood, CO-based UltraGuide, for products addressing this market segment.Medrad, a U.S. subsidiary
Interventional CT represents a strategic opportunity for Medrad. The company has signed its second distribution agreement in three months, this one with Lakewood, CO-based UltraGuide, for products addressing this market segment.
Medrad, a U.S. subsidiary of Schering, agreed in January to begin distributing UltraGuide's CT-Guide in the U.S. and France. The visual guidance system designed for minimally invasive CT procedures will be marketed along with SimpliCT, a CT guidance device manufactured by NeoRad. A distribution agreement for SimpliCT was signed in November. Interventional guidance is a natural extension of Medrad's product lines, according to the company, which provides MRI surface coils and power injectors for contrast-enhanced studies.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.